NCT02698839进行中（未招募）不适用
A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, RCT Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 539
- 试验地点
- 1
- 主要终点
- in-stent Late Lumen Loss, 9M
研究概览
简要总结
PIONEER-II RCT trial is a prospective, multicenter, randomized, non-inferiority registry trial. 539 subjects from about 40 interventional cardiology centers in China will be enrolled to evaluate In-stent late lumen loss(LLL) as the primary endpoint at 9 months. And all the subjects will be followed up to 5 years to attain the data of the secondary endpoints.
详细描述
Realizing even more uniform and complete endothelial coverage, BuMA Supreme™ biodegradable drug coating coronary stent system comprises a new generation of biodegradable drug eluting stent under development by SINOMED. BuMA Supreme™ reconfigures BuMA™ DES utilizing a high caliber cobalt chromium platform coated with rapidly degrading PLGA scaffold.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75, male or non-pregnant female
- •Evidence of non-symptomatic ischemia, stable or non-stable angina pectoris or past MI
- •Target lesion is primary and de-novo coronary artery disease
- •The target lesion length ≤ 60 mm, diameter 2.25mm-5.0mm (visually estimated)
- •Lesion diameter stenosis ≥70% (visually estimated)
- •For each target lesion, same stent implantation only
- •Acceptable candidate for coronary artery bypass grafting (CABG)
- •Understand the study purpose, willing to participate and sign the letter of consent, agrees to the follow-up visits including a 9 month angiographic follow-up
排除标准
- •Acute MI within 1 week
- •Chronic total occlusion(TIMI 0), left main lesion, intervention-required three-vessel lesions, branch vessel diameter ≥ 2.5mm and bypass lesion
- •More than 3 stents required
- •Patients refuse to be implanted stent
- •Calcified lesion failed in pre-dilation, twisted lesion and lesion unsuitable for stent delivery and expansion
- •In-stent restenosis
- •Planned percutaneous coronary intervention (PCI) within 3 months post procedure
- •Other stents implanted within 1 year
- •Severe heart failure (NYHA above III) or left ventricle ejection fraction (EF) <40%
- •Renal function damage, blood creatinine > 176.82 μmol/L
- •Bleeding tendency, active peptic ulcer disease, cerebral or subarachnoid hemorrhage, cerebral apoplexy within half year and contraindication for any anti-platelet or anticoagulation agents
- •Allergic to drugs or agents used in stent or protocol (PLGA, sirolimus, aspirin, clopidogrel, contrast agent, cobalt, nickel, chromium, iron, wolfram et. al.)
- •Life expectation < 12 months
- •Have not reached the primary end point when participating in other trial
- •Poor compliance to the protocol
- •Heart implantation cases
结局指标
主要结局
in-stent Late Lumen Loss, 9M
时间窗: QCA at 9-month follow-up window
The primary endpoint is in-stent Late Lumen Loss (LLL) at 9-month after stent implantation as assessed by off-line quantitative coronary angiography (QCA).
次要结局
- Academic Research Consortium(ARC) defined stent thrombosis(5 years after PCI)
- Stent implantation success rate(5 years after PCI)
- diameter stenosis degree(9 months)
- in-segment LLL(9 months)
- Binary restenosis rate(9 months)
- Device-oriented Composite Endpoint (DoCE)(1, 6, 12 month, and annually up to 5 years post procedure)
- Patient-oriented Composite Endpoint (PoCE)(1, 6, 12 month, and annually up to 5 years post procedure)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A prospective phase II, randomized multi-center trial of a combined modularized treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with squamous cell lung cancer and non- squamous cell lung cancer, respectively after platin failure (ModuLung)EUCTR2014-004095-31-DEFreistaat Bayer respresented by University of Regensburg represented by Kaufmännischer Direktor86
进行中（未招募）
1 期
A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplantation - Sirolimus and Hepatitis C following Liver TransplantatioPatients who have undergone liver transplantation and are infected with Hepatitis C virus.MedDRA version: 9.1 Level: HLT Classification code 10052779 Term: Transplant rejectionsMedDRA version: 9.1 Level: HLGT Classification code 10024970 Term: Respiratory tract infectionsMedDRA version: 9.1 Level: HLT Classification code 10046577 Term: Urinary tract infectionsMedDRA version: 9.1 Level: LLT Classification code 10001032 Term: Acute pyelonephritisMedDRA version: 9.1 Level: LLT Classification code 10040072 Term: SepticaemiaMedDRA version: 9.1 Level: HLT Classification code 10019972 Term: Herpes viral infectionsMedDRA version: 9.1 Level: HLGT Classification code 10028440 Term: Mycobacterial infectious disordersMedDRA version: 9.1 Level: HLT Classification code 10015107 Term: Epstein-Barr viral infectionsMedDRA version: 9.1 Level: LLT Classification code 10011831 Term: Cytomegalovirus infectionMedDRA version: 9.1 Level: LLT Classification code 10019974 Term: Herpes zosterMedDRA version: 9.1 Level: LLT Classification code 10058872 Term: Fungal sepsisMedDRAEUCTR2008-000252-28-GBCambridge University Hospitals NHS Foundation Trust
进行中（未招募）
1 期
Prospective Randomized Multicenter Phase II Trial toInvestigate Intensified Neoadjuvant Chemotherapy inLocally Advanced Pancreatic Cancerocally advanced pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2013-004796-12-DEAIO-Studien-gGmbH168
进行中（未招募）
不适用
Trial that evaluates the combination treatment of Trabectedin and Radiotherapy in Soft Tissue Sarcoma patients.Soft Tissue SarcomaEUCTR2014-001549-26-ESGEIS96
尚未招募
2 期
A MultiCenter Prospective Randomized Phase II Clinical Trial to Evaluate Safety and Efficacy of Hyalospine® in Lumbar Laminectomy or Laminotomy.NL-OMON32769Fidia Advanced Biopolymers (FAB) S.r.l.32